Measurement of Kidney Blood Flow and Oxygen Levels by MRI

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Rocco, Wake Forest School of Medicine
ClinicalTrials.gov Identifier:
NCT01318967
First received: March 18, 2011
Last updated: April 8, 2015
Last verified: April 2015
Results First Received: December 8, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Condition: Chronic Kidney Disease
Intervention: Drug: Furosemide

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Furosemide

With and without furosemide

Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.


Participant Flow:   Overall Study
    Furosemide  
STARTED     10  
COMPLETED     10  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Furosemide

With and without furosemide

Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide.


Baseline Measures
    Furosemide  
Number of Participants  
[units: participants]
  10  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     8  
>=65 years     2  
Gender  
[units: participants]
 
Female     6  
Male     4  
Region of Enrollment  
[units: participants]
 
United States     10  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Measurement of Renal Blood Flow of the Kidney by Both the PAH Method and by MRI   [ Time Frame: Renal blood flow is estimated over 1 hour by PAH and 30 minutes by MRI (day 1) ]

2.  Secondary:   Measurement of Regional Blood Oxygenation by MRI   [ Time Frame: One measure after furosemide (day 1) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Michael Rocco, MD
Organization: Wake Forest School of Medicine
phone: 336-716-4650
e-mail: mrocco@wfubmc.edu


No publications provided


Responsible Party: Michael Rocco, Wake Forest School of Medicine
ClinicalTrials.gov Identifier: NCT01318967     History of Changes
Other Study ID Numbers: 0537GCRC
Study First Received: March 18, 2011
Results First Received: December 8, 2014
Last Updated: April 8, 2015
Health Authority: United States: Institutional Review Board